Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02956122 · ClinicalTrials.gov registry record · Phase 2
A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
A Phase 2 study, sponsored by Baxalta now part of Shire.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02956122 is a Phase 2 study that was terminated before completion, run by Baxalta now part of Shire. The registered enrollment target is 1 participants.
The verdict
NCT02956122, a Phase 2 study, was terminated before completion, sponsored by Baxalta now part of Shire.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of GLASSIA as an add-on biopharmacotherapy to standard-of-care steroid treatment as the first-line treatment in participants with acute GvHD with lower GI involvement.
Interventions
- BIOLOGICAL Albumin
- BIOLOGICAL GLASSIA
- DRUG methylprednisolone or equivalent steroid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-04-26 |
| Est. Completion | 2018-05-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02956122
The ClinicalTrials.gov registry entry for NCT02956122 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Albumin is the first listed.
NCT02956122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02956122 about?
NCT02956122 is a clinical study titled "A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD". The purpose of the study is to evaluate the safety and efficacy of GLASSIA as an add-on biopharmacotherapy to standard-of-care steroid treatment as the first-line treatment in participants with acute GvHD with lower GI involvement.
What is the current status of trial NCT02956122?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2017-04-26. Estimated completion is 2018-05-03.
What interventions are being tested in trial NCT02956122?
The interventions under investigation include: Albumin (BIOLOGICAL), GLASSIA (BIOLOGICAL), methylprednisolone or equivalent steroid (DRUG).
Who is sponsoring clinical trial NCT02956122?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.